NAC for Attenuation of COVID-19 Symptomatology

The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.

STUDY DESIGN: Randomized double-blinded placebo-controlled trial ELIGIBILITY Inclusion criteria: * age 18 years and older * participants will need daily access to use of a smartphone for at least six weeks from time of enrollment * Positive COVID-19 test within 10 days of date of enrollment * not already hospitalized for treatment of COVID Exclusion criteria: * pregnant * already hospitalized for treatment of COVID PROTOCOL * 50:50 randomization: half of participants will take NAC, half will take placebo * Participants will take NAC/placebo following this outpatient protocol: * 2400 mg x 1 PO then * 1200 mg PO BID x 14 days * Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)